Long-Term Outcomes of Subthalamic Nucleus and Globus Pallidus Interna Deep Brain Stimulation for Young-Onset Parkinson Disease
Authors:
- Grace E. HeyGHGrace E. Hey
- Hikaru KamoHKHikaru Kamo
- Gilberto Perez Rodriguez GarciaGGGilberto Perez Rodriguez Garcia
- Tejas R. MehtaTMTejas R. Mehta
- Robert Stephen EisingerRERobert Stephen Eisinger
- Michael S. OkunMOMichael S. Okun
- Justin D. HilliardJHJustin D. Hilliard
- Kelly D. FooteKFKelly D. Foote
- Adolfo Ramirez-ZamoraAdolfo Ramirez-Zamora
- 1 June 2026
- journal article
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (3) , e200605
Abstract
Patients with young-onset Parkinson disease (YOPD) commonly experience early motor complications necessitating deep brain stimulation (DBS), and the subthalamic nucleus (STN) and globus pallidus interna (GPi) are the primary DBS targets used for reducing medication use and addressing dyskinesias. This study leveraged both the University of Florida Fixel Institute high volume of DBS operations and the INFORM database to evaluate motor outcomes in a large cohort of patients with YOPD treated with STN or GPi DBS, and addressed the limited available evidence and paucity of data on the long-term effects of these targets applied to YOPD. A single-center retrospective chart review was conducted on a nonrandomized cohort of adult patients with a diagnosis of YOPD treated with STN or GPi DBS between January 1999 and October 2023. Multidisciplinary evaluation was used to choose the anatomical target for each patient. Disease onset, lead location, medications, and mortality were collected and compared between cohorts. Preoperative, 6-month, and 1-, 3-, and 5-year Unified Parkinson's Disease Rating Scale (UPDRS) scores were used to compare motor outcomes. There were 405 patients, and 61.3% received GPi DBS and 37.7% STN DBS. Mean disease duration at surgery was 12.3 (4.2) years for GPi and 11.5 (6.3) years for STN. GPi DBS improved ON UPDRS part 3 scores at 1 year (26.5 [11.84] vs 20.94 [9.09], p = 0.0024), and these scores worsened slightly by 5-year follow-up (20.94 [9.09] vs 24.72 [10.28], p = 0.0491). Unilateral STN DBS showed greater 6-month motor improvement vs unilateral GPi (p < 0.001) and remained stable from 6 months to 3 years (p = 0.3). GPi DBS improved ON UPDRS part 4 scores from baseline to 5 years (8.34 [3.15] vs 4.21 [2.25], p < 0.0001), whereas STN DBS showed no significant change (6.16 [4.21] vs 5.0 [2.98], p = 0.328). Although statistically significant, the changes did not meet the threshold for clinical relevance. This large cohort study assessed long-term outcomes of STN vs GPi DBS when used in the setting of YOPD. Both targets improved motor symptoms at 1 and 5 years. STN offered modest motor benefits and greater medication reduction, while GPi DBS better addressed dyskinesia and motor fluctuations. These findings inform preoperative decision-making, although selection bias based on baseline symptoms remains a limitation of the data set.Keywords
This publication has 28 references indexed in Scilit:
- Global prevalence and incidence of Young Onset Parkinson’s disease: A systematic review and meta-analysisJournal of Clinical Neuroscience, 2024
- Pathogenesis of Parkinson’s disease: from hints from monogenic familial PD to biomarkersJournal of Neural Transmission, 2024
- The pathogenesis of Parkinson's diseaseThe Lancet, 2024
- Eleven-Year Outcomes of Deep Brain Stimulation in Early-Stage Parkinson DiseaseNeuromodulation: Technology at the Neural Interface, 2022
- Parkinson's diseaseThe Lancet, 2021
- Age-dependent efficacy of subthalamic nucleus deep brain stimulation in young- and late-onset Parkinson's disease based on a 10 year follow-upJournal of the Neurological Sciences, 2020
- STN vs. GPi deep brain stimulation for tremor suppression in Parkinson disease: A systematic review and meta-analysisParkinsonism & Related Disorders, 2018
- Long-term outcome of young onset Parkinson's disease after subthalamic stimulation—A cross-sectional studyClinical Neurology and Neurosurgery, 2013
- Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson’s diseaseJournal of Neurology, 2012
- The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendationsMovement Disorders, 2003